Biogen Inc.(BIIB) Stock Research - Grey Stern Research
Loading...

Biogen Inc. (BIIB) Stock Analysis

$173.04 (-0.51%)

BIIB Financial Performance


Use the table below to view Biogen Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q2 - 2024

Metric Value Ranking among Peers
Price $173.04 -
52 Week Low $170.71 -
52 Week High $268.30 -
Market Cap $25.2 Billion 11/11
Gross Margin 78% 3/11
Profit Margin 24% 3/11
EBITDA margin 28% 8/11
Q2 - 2024 Revenue $2.5 Billion 11/11
Q2 - 2024 Earnings $583.6 Million 10/11
Q2 - 2024 Free Cash Flow $0 Million 8/11
Trailing 4 Quarters Revenue $9.6 Billion 11/11
Trailing 4 Quarters Earnings $1.2 Billion 8/11
Quarterly Earnings Growth -1% 5/11
Annual Earnings Growth -34% 5/11
Quarterly Revenue Growth 0% 11/11
Annual Revenue Growth -3% 8/11
Cash On Hand $1.9 Billion 9/11
Short Term Debt $0 10/11
Long Term Debt $6.7 Billion 10/11

Biogen Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Biogen Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 21.76 5/11
PS 2.63 8/11
PB 1.59 11/11
PC 13.21 10/11
Liabilities to Equity 0.69 10/11
ROA 0.04 5/11
ROE 0.07 8/11
Current Ratio 2.46 1/11
Quick Ratio 0.17 2/11
Long Term Debt to Equity 0.42 9/11
Debt to Equity 0.42 9/11
Burn Rate -6.02 8/11
Cash to Cap 0.08 1/11
CCR 0.00 8/11
EV to EBITDA 42.89 5/11
EV to Revenue 3.13 9/11

Company Details

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

CEO: Mr. Michel Vounatsos

Website: https://www.biogen.com

Address: 225 Binney St Cambridge, MASSACHUSETTS

Exchange: NASDAQ Global Select

Industry: Drug Manufacturers—General

Biogen Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Biogen Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Pfizer Inc. PFE $151.4 Billion
Bristol-Myers Squibb Company BMY $109.8 Billion
Gilead Sciences, Inc. GILD $120.2 Billion
AbbVie Inc. ABBV $352.4 Billion
Merck & Co., Inc. MRK $260.9 Billion
Johnson & Johnson JNJ $374.3 Billion
GSK plc GSK $74.0 Billion
Amgen Inc. AMGN $174.8 Billion
Novartis AG NVS $208.3 Billion
Sanofi SNY $128.7 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
BIIB Income Statements
Quarter Year Revenue Earnings
Q2 2024 $ 2.5 Billion $583.6 Million
Q1 2024 $ 2.2 Billion $393.4 Million
Q4 2023 $ 2.4 Billion $249.7 Million
Q3 2023 $ 2.5 Billion -$68.1 Million
Q2 2023 $ 2.5 Billion $591.6 Million
Q1 2023 $ 2.5 Billion $387.9 Million
Q4 2022 $ 2.5 Billion $550.4 Million
Q3 2022 $ 2.5 Billion $1.1 Billion

View All

BIIB Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q2 2024 $1.9 Billion $26.8 Billion $6.7 Billion $15.9 Billion
Q1 2024 $1.1 Billion $26.6 Billion $6.9 Billion $15.2 Billion
Q4 2023 $12.5 Million $77.7 Million $0 $0
Q3 2023 $2.3 Billion $28.2 Billion $7.7 Billion $14.5 Billion
Q2 2023 $2.6 Billion $25.2 Billion $6.6 Billion $14.5 Billion
Q1 2023 $2.9 Billion $24.6 Billion $6.6 Billion $13.8 Billion
Q4 2022 $3.4 Billion $24.6 Billion $6.6 Billion $13.4 Billion
Q3 2022 $3.7 Billion $24.9 Billion $6.6 Billion $14.0 Billion

View All

BIIB Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q2 2024 $0 $0 $0
Q1 2024 $432.3 Million -$120.9 Million $24.5 Million
Q4 2023 $65.2 Million $65.2 Million -$1.3 Billion
Q3 2023 $504.8 Million -$87.6 Million -$329.9 Million
Q2 2023 $400.0 Million -$87.0 Million -$280.4 Million
Q1 2023 $383.7 Million -$71.6 Million -$521.1 Million
Q4 2022 -$262.4 Million -$87.4 Million -$256.3 Million
Q3 2022 -$81.5 Million $155.8 Million $1.1 Billion

View All